Offers 29% premium for biotech partner; shares soar
(Newser) -
Already a 17% shareholder, Bristol-Myers Squibb laid down a $4.5 billion offer to buy the rest of ImClone shares, the Wall Street Journal reports. The $60-a-share offer, sent to ImClone chairman Carl Icahn today, is a 29% premium on yesterday's closing price and makes Bristol the second pharma giant...